GSK’s Advil Dual Action in Combination with Acetaminophen Receives the US FDA’s Approval for Pain Relief

 GSK’s Advil Dual Action in Combination with Acetaminophen Receives the US FDA’s Approval for Pain Relief

GSK Reports Submission of NDA to MHLW for Daprodustat to Treat Patients with Renal Anaemia due to Chronic Kidney Disease in Japan

Shots:

  • The approval is based on seven clinical studies including three of which were pivotal efficacy and safety studies in pain relief which involves assessing of ibuprofen (250 mg) + acetaminophen (500 mg) vs ibuprofen and acetaminophen monothx in patients with acute pain symptoms
  • The study demonstrated that the FD combination achieved superior efficacy then the monotherapy in patients
  • Advil Dual Action is combination of ibuprofen and acetaminophen resulting to an exclusive pain reliever and will be available over-the-counter nationwide in 2020

Click here to read full press release/ article | Ref: PRNewswire | Image: Signbox

Shiwani Sharma

Shiwani Sharma is a Senior Editor at PharmaShots. She has in-depth knowledge of lifesciences industry including pharma and biotech sectors. She also covers news in field of Digital Health, Medtech and regulatory approvals from the US FDA, EU, and other global regulatory bodies in the industry. Additionally, she also writes Whitepapers, analysis reports, blogs on pharma and biotech industry. She is graduate in Biotechnology. She can be contacted on shiwani@pharmashots.com

Related post